| Event | Date |
|---|---|
| Open Date | 08-12-2025 , Monday |
| Close Date | 10-12-2025 , Wednesday |
| Tentative Allotment | 11-12-2025 , Thursday |
| Tentative Listing Date | 15-12-2025 , Monday |
| Retail Appl. Cut Off Time | 10-12-2025 , Wednesday 05:00 PM |
| Non Retail Appl. Cut Off Time | 10-12-2025 , Wednesday 04:00 PM |
| Anchor Allotment | 05-12-2025 , Friday |
| Initiation Of Refund | 12-12-2025 , Friday |
| Credit Of Share To Demat | 12-12-2025 , Friday |
Corona Remedies Limited is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.
The company mainly operates in the domestic branded formulation market. Its business depends on doctor prescriptions, brand strength, medical representative productivity, product launches, therapy focus, manufacturing quality and distribution reach.
Corona Remedies develops, manufactures and markets branded pharmaceutical formulations. The company primarily offers its products in India across women’s health, cardio-diabeto, pain management, urology and other / multispecialty pharmaceutical products comprising VMN, gastrointestinal and respiratory products.
| Business Area | Meaning |
|---|---|
| Branded formulations | Medicines sold under company-owned or acquired brands |
| Women’s healthcare | Gynecology and female healthcare formulations |
| Cardio-diabeto | Cardiovascular and diabetes-related products |
| Pain management | Pain, analgesic and neuro/CNS-related products |
| Urology | Urology and related medicines |
| Others / multispecialty | VMN, gastrointestinal, respiratory and other products |
| Manufacturing | Own manufacturing facilities in Gujarat and Himachal Pradesh |
| Marketing and distribution | Doctor prescription-led sales through field force and distribution network |
IPORupee View: In branded pharma, the company’s real assets are not only factories. The bigger assets are brands, prescription strength, doctor relationships, field force reach and therapy positioning. If doctors continue prescribing the company’s products, sales can remain sticky.
Corona Remedies operates in focused therapeutic areas. The table below shows MAT June 2025 domestic sales, market rank and CAGR comparison with the Indian Pharmaceutical Market.
| Addressable Market | MAT June 2025 Domestic Sales | % of Domestic Sales | Market Rank MAT June 2025 | Corona CAGR MAT June 2022 to MAT June 2025 | IPM CAGR MAT June 2022 to MAT June 2025 |
|---|---|---|---|---|---|
| Women’s Healthcare | Rs. 4,080.26 mn | 28.56% | 6 | 20.67% | 9.10% |
| Cardio-diabeto | Rs. 3,339.96 mn | 23.38% | 22 | 21.95% | 9.74% |
| Pain Management | Rs. 1,684.38 mn | 11.79% | 5 | 19.20% | 12.27% |
| Urology | Rs. 646.65 mn | 4.53% | 9 | 59.56% | 16.75% |
| Others | Rs. 4,533.64 mn | 31.74% | NA | 7.45% | NA |
| Total | Rs. 14,284.89 mn | 100.00% | 29 | 16.77% | 9.21% |
IPORupee View: This table is very important because it shows that Corona Remedies is growing faster than the Indian Pharmaceutical Market in its major therapy areas. Urology is the strongest growth area, with 59.56% CAGR compared with IPM CAGR of 16.75%. Women’s healthcare, cardio-diabeto and pain management also grew faster than the market.
| Therapeutic Area | MAT June 2025 Sales | % Domestic Sales | MAT June 2024 Sales | % Domestic Sales | MAT June 2023 Sales | % Domestic Sales | MAT June 2022 Sales | % Domestic Sales |
|---|---|---|---|---|---|---|---|---|
| Women’s Healthcare | Rs. 4,080.26 mn | 28.56% | Rs. 3,489.78 mn | 27.75% | Rs. 3,114.22 mn | 28.26% | Rs. 2,322.11 mn | 25.88% |
| Cardio-diabeto | Rs. 3,339.96 mn | 23.38% | Rs. 2,963.95 mn | 23.57% | Rs. 2,366.69 mn | 21.48% | Rs. 1,841.75 mn | 20.53% |
| Pain Management | Rs. 1,684.38 mn | 11.79% | Rs. 1,345.06 mn | 10.69% | Rs. 1,069.27 mn | 9.70% | Rs. 994.43 mn | 11.08% |
| Urology | Rs. 646.65 mn | 4.53% | Rs. 267.26 mn | 2.13% | Rs. 194.30 mn | 1.76% | Rs. 159.17 mn | 1.77% |
| Others | Rs. 4,533.64 mn | 31.74% | Rs. 4,510.68 mn | 35.87% | Rs. 4,276.13 mn | 38.80% | Rs. 3,654.05 mn | 40.73% |
| Total | Rs. 14,284.89 mn | 100.00% | Rs. 12,576.74 mn | 100.00% | Rs. 11,020.62 mn | 100.00% | Rs. 8,971.51 mn | 100.00% |
IPORupee View: Women’s healthcare and cardio-diabeto together contributed 51.94% of domestic sales for MAT June 2025. This gives the company a focused therapy profile. Urology is small at 4.53% of sales, but it is growing very fast and can become an important future growth area.
Corona Remedies has several important brands across gynecology, cardio-diabeto, pain management and urology.
| Therapy Area | Brand | Domestic Sales MAT June 2025 | Contribution to Domestic Sales | Sub-group Ranking MAT June 2025 |
|---|---|---|---|---|
| Gynaecology | C-HOP | Rs. 365.81 mn | 2.56% | 5 |
| Gynaecology | Trazer | Rs. 327.24 mn | 2.29% | 1 |
| Gynaecology | COR | Rs. 386.60 mn | 2.71% | 1 |
| Cardio-diabeto | Cortel | Rs. 724.86 mn | 5.07% | 17 |
| Cardio-diabeto | Rosuless | Rs. 596.88 mn | 4.18% | 15 |
| Cardio-diabeto | Bisobis | Rs. 203.46 mn | 1.42% | 5 |
| Cardio-diabeto | Obimet | Rs. 613.93 mn | 4.30% | 18 |
| Cardio-diabeto | Sitabite | Rs. 283.38 mn | 1.98% | 24 |
| Cardio-diabeto | Dapabite | Rs. 181.84 mn | 1.27% | 17 |
| Pain Management | Myoril | Rs. 963.56 mn | 6.75% | 1 |
| Pain Management | GB 29 | Rs. 459.14 mn | 3.21% | 8 |
| Pain Management | Etowin | Rs. 127.04 mn | 0.89% | 10 |
| Urology | Dosin | Rs. 269.68 mn | 1.89% | 9 |
| Urology | Alkashot | Rs. 130.07 mn | 0.91% | 3 |
| Urology | Tamdosin | Rs. 112.97 mn | 0.79% | 10 |
IPORupee View: This section shows the brand strength of the company. In branded pharma, brands are the real business asset. Myoril has sub-group rank 1 and contributed 6.75% of domestic sales. Trazer and COR also have sub-group rank 1 in gynaecology. Cortel, Rosuless and Obimet are important cardio-diabeto brands.
| Brand | MAT June 2025 Domestic Sales | % of Total Domestic Sales | Domestic Sales CAGR MAT June 2022 to MAT June 2025 |
|---|---|---|---|
| B-29 | Rs. 1,506.37 mn | 10.55% | 20.07% |
| Myoril | Rs. 963.56 mn | 6.75% | 35.63% |
| Tricium | Rs. 758.10 mn | 5.31% | 17.80% |
| Cortel | Rs. 724.86 mn | 5.07% | 13.42% |
| Obimet | Rs. 613.93 mn | 4.30% | 22.25% |
IPORupee View: The top five brands contributed around 31.98% of total domestic sales in MAT June 2025. This is positive because the company has strong brands, but retail investors should also check brand concentration. If a few brands contribute a large share of sales, any slowdown, competition or pricing pressure in those brands can affect growth.
Corona Remedies has also grown by acquiring brand portfolios from established pharmaceutical companies.
| Year of Acquisition | Brand Portfolio Acquired From | Domestic Sales in Year of Acquisition | Domestic Sales MAT June 2025 | CAGR |
|---|---|---|---|---|
| 2017 | GlaxoSmithKline Pharmaceuticals Limited portfolio comprising Dilo DX, Dilo BM, Vitneurin, Stelbid | Rs. 7.28 mn | Rs. 652.25 mn | 75.40% |
| 2018 | Abbott India Limited portfolio comprising Thyrocab, Obimet range and Triobimet | Rs. 244.92 mn | Rs. 700.39 mn | 16.19% |
| 2023 | Sanofi Healthcare India Private Limited portfolio comprising Myoril | Rs. 417.75 mn | Rs. 963.56 mn | 51.87% |
| 2025 | Bayer Zydus Pharma Private Limited portfolio comprising Fostine, Mendac, Luprofact, Ovidac, Spye, Vageston and Noklot | Rs. 80.07 mn | Rs. 80.07 mn | NA |
IPORupee View: This shows that Corona Remedies is not only launching its own products but also acquiring established brands and scaling them. The Myoril acquisition is especially important. Myoril sales increased from Rs. 417.75 million at acquisition to Rs. 963.56 million in MAT June 2025. The GSK portfolio also grew strongly from Rs. 7.28 million to Rs. 652.25 million.
Corona Remedies is strongly India-focused. More than 96% of revenue from operations comes from India in all reported periods.
| Geography | Three Months Ended June 30, 2025 | % of Revenue | FY2025 | % of Revenue | FY2024 | % of Revenue | FY2023 | % of Revenue |
|---|---|---|---|---|---|---|---|---|
| Within India | Rs. 3,338.54 mn | 96.34% | Rs. 11,524.56 mn | 96.33% | Rs. 9,802.28 mn | 96.62% | Rs. 8,521.61 mn | 96.39% |
| Outside India | Rs. 126.88 mn | 3.66% | Rs. 439.59 mn | 3.67% | Rs. 342.46 mn | 3.38% | Rs. 318.89 mn | 3.61% |
| Total Revenue from Operations | Rs. 3,465.42 mn | 100.00% | Rs. 11,964.15 mn | 100.00% | Rs. 10,144.74 mn | 100.00% | Rs. 8,840.50 mn | 100.00% |
IPORupee View: This is a clear domestic pharma story. Around 96% of revenue from operations comes from India. This reduces exposure to USFDA-type export risk and global pricing pressure, but also means the company is heavily dependent on the Indian Pharmaceutical Market, domestic doctor prescriptions, pricing regulations and Indian distribution reach.
Corona Remedies operates manufacturing facilities in Gujarat and Himachal Pradesh and is in the process of commissioning a hormone manufacturing facility in Gujarat.
| Manufacturing Area | Importance |
|---|---|
| Gujarat facility | Supports formulation manufacturing |
| Himachal Pradesh facility | Supports formulation manufacturing |
| Proposed hormone facility in Gujarat | Important for women’s healthcare and hormone-related therapies |
| Owned manufacturing share | 64.01% of FY2025 revenue from operations came from owned manufacturing |
IPORupee View: Owned manufacturing gives better control over quality, supply and margins. The proposed hormone facility is strategically important because women’s healthcare is the company’s largest focused therapy area. However, pharma manufacturing also brings regulatory, quality-control, plant-utilisation and compliance risks.
| Particulars | Unit | Three Months Ended June 30, 2025 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|---|
| Revenue from operations | Rs. million | 3,465.42 | 11,964.15 | 10,144.74 | 8,840.50 |
| Growth of revenue from operations | % | NA | 17.93% | 14.75% | NA |
| Domestic revenue as % of total revenue | % | 96.34% | 96.33% | 96.62% | 96.39% |
| International revenue as % of total revenue | % | 3.66% | 3.67% | 3.38% | 3.61% |
| Owned manufacturing revenue as % of total revenue | % | 62.75% | 64.01% | 64.52% | 62.02% |
| Gross Profit | Rs. million | 2,807.62 | 9,599.04 | 7,876.46 | 6,730.96 |
| Growth of Gross Profit | % | NA | 21.87% | 17.02% | NA |
| Gross Profit Margin | % | 81.02% | 80.23% | 77.64% | 76.14% |
| EBITDA | Rs. million | 717.96 | 2,459.13 | 1,611.90 | 1,350.30 |
| Growth of EBITDA | % | NA | 52.56% | 19.37% | NA |
| EBITDA Margin | % | 20.72% | 20.55% | 15.89% | 15.27% |
| Profit After Tax | Rs. million | 461.96 | 1,494.34 | 905.03 | 849.29 |
| Growth of PAT | % | NA | 65.11% | 6.56% | NA |
| PAT Margin | % | 13.33% | 12.49% | 8.92% | 9.61% |
| ROCE | % | 11.28% | 41.32% | 31.19% | 28.36% |
| Adjusted ROCE | % | 14.53% | 47.87% | 37.53% | 36.62% |
| ROE | % | 7.61% | 27.50% | 20.36% | 23.29% |
| OCF / EBITDA | % | 35.33% | 77.46% | 97.25% | 76.06% |
| Net Working Capital Days | Days | 68.62 | 24.17 | 23.43 | 31.20 |
| Net Debt / Net Cash | Rs. million | Net cash 179.99 | Net cash 66.40 | Net debt 621.20 | Net cash 952.47 |
IPORupee Financial Insight: Revenue from operations increased from Rs. 8,840.50 million in FY2023 to Rs. 11,964.15 million in FY2025. EBITDA increased from Rs. 1,350.30 million to Rs. 2,459.13 million, and PAT increased from Rs. 849.29 million to Rs. 1,494.34 million during the same period.
The strongest point is margin improvement. Gross profit margin improved from 76.14% in FY2023 to 80.23% in FY2025, EBITDA margin improved from 15.27% to 20.55%, and PAT margin improved from 9.61% to 12.49%.
Net working capital days increased to 68.62 days for the three months ended June 30, 2025, compared with 24.17 days in FY2025. OCF / EBITDA also reduced to 35.33% for the three months ended June 30, 2025. This may be seasonal or temporary, but investors should monitor receivables, inventory and cash conversion.
As of June 30, 2025, Corona Remedies had 4,573 permanent employees. Its workforce is a critical factor in maintaining quality, safety, operational excellence and prescription-led sales.
| Function | Number of Employees |
|---|---|
| Corporate | 223 |
| Manufacturing | 294 |
| Operations | 144 |
| Quality | 220 |
| R&D | 103 |
| Sales & Marketing | 3,589 |
| Total | 4,573 |
IPORupee View: This is a very important point. Out of 4,573 permanent employees, 3,589 employees are in Sales & Marketing. This clearly shows that Corona Remedies is a prescription-driven branded pharma company. The medical representative field force is the bridge between the company and doctors.
The company relies on trademarks, trade secrets, know-how and confidentiality agreements to strengthen its competitive position.
IPORupee View: In branded pharma, trademarks matter because brand recall drives prescription and repeat sales. Pending or opposed trademarks are a watch point. If a company cannot protect important product brands, it may face brand confusion, legal disputes or marketing limitations.
Corona Remedies IPO is a book-built issue consisting entirely of an Offer for Sale. The company will not receive fresh capital from the IPO.
| Particulars | Details |
|---|---|
| IPO Size | Rs. 655.37 crore |
| Fresh Issue | Nil |
| Offer for Sale | Rs. 655.37 crore |
| Shares Offered | 61,71,101 shares |
| Price Band | Rs. 1,008 to Rs. 1,062 per share |
| Face Value | Rs. 10 per share |
| Lot Size | 14 shares |
| Minimum Retail Application at Upper Band | Rs. 14,868 |
| Listing | BSE and NSE |
This is a 100% Offer for Sale IPO. That means the IPO proceeds will go to selling shareholders, not to the company. This is not automatically negative, but investors should not treat the IPO as fresh growth capital for the company.
The company is focused on branded formulations mainly in India.
Total domestic sales grew at 16.77% CAGR versus IPM CAGR of 9.21%.
Women’s healthcare, cardio-diabeto, pain management and urology are important therapeutic areas.
Women’s healthcare contributed 28.56% of domestic sales in MAT June 2025.
Cardio-diabeto contributed 23.38% of domestic sales in MAT June 2025.
Urology grew at 59.56% CAGR between MAT June 2022 and MAT June 2025.
B-29, Myoril, Tricium, Cortel and Obimet are important sales contributors.
Acquired portfolios from GSK, Abbott, Sanofi and Bayer Zydus show acquisition-led growth ability.
EBITDA margin improved from 15.27% in FY2023 to 20.55% in FY2025.
Corona Remedies Limited is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.
The company’s business is highly prescription-driven and domestic market focused. More than 96% of revenue from operations comes from India, and 64.01% of FY2025 revenue was generated from owned manufacturing.
Corona Remedies has strong therapy positioning. In MAT June 2025, women’s healthcare contributed 28.56% of domestic sales, cardio-diabeto contributed 23.38%, pain management contributed 11.79% and urology contributed 4.53%.
The company is growing faster than the Indian Pharmaceutical Market in its covered therapies. Its total domestic sales CAGR from MAT June 2022 to MAT June 2025 was 16.77%, compared with IPM CAGR of 9.21%.
This is not an API or export-heavy pharma company. It is mainly an Indian branded formulation company.
Total domestic sales grew at 16.77% CAGR compared with IPM CAGR of 9.21%.
Women’s healthcare contributed 28.56% of domestic sales and had market rank 6 in MAT June 2025.
Cardio-diabeto contributed 23.38% of domestic sales and grew at 21.95% CAGR.
Urology contributed 4.53% of sales but grew at 59.56% CAGR.
B-29, Myoril, Tricium, Cortel and Obimet are major contributors.
Acquired portfolios from GSK, Abbott, Sanofi and Bayer Zydus show ability to acquire and scale brands.
3,589 employees are in Sales & Marketing, confirming prescription-driven business dependence.
Owned manufacturing contributed 64.01% of FY2025 revenue from operations.
Gross margin, EBITDA margin and PAT margin improved between FY2023 and FY2025.
OCF / EBITDA declined to 35.33% and net working capital days increased to 68.62 days in Q1 FY2026.
The company will not receive fresh funds from the IPO.
Corona Remedies Limited is a fast-growing India-focused branded pharmaceutical formulation company with strong positioning in women’s healthcare, cardio-diabeto, pain management and urology.
The company’s key positives are faster-than-market domestic sales growth, focused therapy portfolio, strong brands, improving margins, owned manufacturing contribution, brand acquisition track record and experienced promoter-led management.
The key concerns are 100% OFS structure, domestic concentration, therapy concentration, doctor prescription dependency, sales force dependency, pricing regulation risk, trademark-related risks, manufacturing compliance risk and working capital movement.
This IPO should be studied as a domestic branded pharma growth + prescription-driven formulation + margin expansion story, not as a fresh capital expansion IPO.
| Short Form | Full Form |
|---|---|
| IPO | Initial Public Offering |
| RHP | Red Herring Prospectus |
| OFS | Offer for Sale |
| IPM | Indian Pharmaceutical Market |
| MAT | Moving Annual Total |
| VMN | Vitamins, Minerals and Nutrition |
| NLEM | National List of Essential Medicines |
| EBITDA | Earnings Before Interest, Tax, Depreciation and Amortization |
| PAT | Profit After Tax |
| ROE | Return on Equity |
| ROCE | Return on Capital Employed |
| OCF | Operating Cash Flow |
| API | Active Pharmaceutical Ingredient |
| CNS | Central Nervous System |
| BSE | Bombay Stock Exchange |
| NSE | National Stock Exchange |
| SEBI | Securities and Exchange Board of India |
| CRISIL | Credit Rating Information Services of India Limited |
This content is prepared by IPORupee for educational and informational purposes only. It is based on IPO-related disclosures and information shared for understanding the company’s business model, product portfolio, therapy mix, financial performance, industry position and key risks.
This is not a recommendation to apply, avoid, buy, sell or hold any IPO or security. IPORupee is not a SEBI-registered investment adviser, research analyst, broker, pharma consultant or portfolio manager.
Pharmaceutical businesses are subject to regulatory, clinical, manufacturing, quality, pricing, litigation, product approval, distribution and competition risks. Investors should read the Red Herring Prospectus, risk factors, financial statements, objects of the issue, peer comparison, valuation details and official disclosures carefully and consult their financial advisor before making any investment decision.
| Category | Percentage | No. of Shares Offered | Amount |
|---|---|---|---|
QIB | 50.00 % | 30,58,007 | 324.76 Cr |
Retail | 35.00 % | 21,40,606 | 227.33 Cr |
Total HNI | 15.00 % | 9,17,403 | 97.43 Cr |
SHNI | 5.00 % | 3,05,801 | 32.48 Cr |
BHNI | 10.00 % | 6,11,602 | 64.95 Cr |
Employee | 0.00 % | 58,035 | 5.85 Cr |
CORONA Remedies Ltd allotted 18,34,804 equity shares to anchor investors at ₹1,062 per share on 05 Dec 2025 before the IPO opening. The total anchor allocation stood at 194.86 Cr across 17 anchor investors.
Mutual funds received 13,59,582 shares worth 144.39 Cr, representing 74.10% of the total anchor investor allocation. Within the mutual fund portion, SBI Mutual Fund had the highest fund-house level allocation with 1,41,274 shares worth 15.00 Cr across 1 scheme. Other leading fund houses by allocation included ICICI Prudential Mutual Fund, HDFC Mutual Fund, Kotak Mutual Fund and Axis Mutual Fund.
At scheme level, the largest mutual fund allocations included SBI HEALTHCARE OPPORTUNITIES FUND, ICICI PRUDENTIAL QUALITY FUND, HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUND, MIRAE ASSET HEALTHCARE FUND MIRAHCFD and ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND.
The largest anchor investor received 7.70% of the anchor portion. The top five anchor investors together received 6,65,104 shares, representing about 36.25% of the total anchor allocation.
| Rank | Anchor Investor Name | Shares Allocated | Allocation % | Allocation Amount |
|---|---|---|---|---|
| 1 | SBI HEALTHCARE OPPORTUNITIES FUND | 1,41,274 | 7.70 % | 15.00 Cr |
| 2 | ICICI PRUDENTIAL QUALITY FUND | 1,41,274 | 7.70 % | 15.00 Cr |
| 3 | HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUND | 1,41,274 | 7.70 % | 15.00 Cr |
| 4 | SBI LIFE INSURANCE CO. LTD | 1,24,312 | 6.78 % | 13.20 Cr |
| 5 | MIRAE ASSET HEALTHCARE FUND MIRAHCFD | 1,16,970 | 6.38 % | 12.42 Cr |
| Rank | Mutual Fund Scheme | AMC | Shares Allocated | Allocation % | Allocation Amount |
|---|---|---|---|---|---|
| 1 | SBI HEALTHCARE OPPORTUNITIES FUND | SBI Mutual Fund | 1,41,274 | 7.70 % | 15.00 Cr |
| 2 | ICICI PRUDENTIAL QUALITY FUND | ICICI Prudential Mutual Fund | 1,41,274 | 7.70 % | 15.00 Cr |
| 3 | HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUND | HDFC Mutual Fund | 1,41,274 | 7.70 % | 15.00 Cr |
| 4 | MIRAE ASSET HEALTHCARE FUND MIRAHCFD | Mirae Asset Mutual Fund | 1,16,970 | 6.38 % | 12.42 Cr |
| 5 | ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 1,16,970 | 6.38 % | 12.42 Cr |
The figures are based on the company’s stock exchange anchor allotment intimation. Anchor allocation is only an informational disclosure and does not indicate future listing performance.
| Application | Discount | Qty (Lot) | Total |
|---|---|---|---|
Retail MIN | - | 14 (1) | ₹ 14,868 |
Retail MAX | - | 182 (13) | ₹ 1,93,284 |
SHNI MIN | - | 196 (14) | ₹ 2,08,152 |
SHNI MAX | - | 938 (67) | ₹ 9,96,156 |
BHNI MIN | - | 952 (68) | ₹ 10,11,024 |
Employee MIN | ₹ 54 | 14 (1) | ₹ 14,112 |
Employee MAX | ₹ 54 | 490 (35) | ₹ 4,93,920 |
| Objective | No Of Shares | Amount |
|---|---|---|
Offer for Sale | - | 655.37 Cr |
| Name | Contact Person | Telephone | Website | |
|---|---|---|---|---|
JM Financial Limited | Prachee Dhuri | +91 22 6630 3030 | corona.ipo@jmfl.com | www.jmfl.com |
IIFL Capital Services Limited | Mansi Sampat / Pawan Kumar Jain | +91 22 4646 4728 | corona.ipo@iiflcap.com | www.iiflcapital.com |
Kotak Mahindra Capital Company Limited | Ganesh Rane | +91 22 4336 0000 | coronaremedies.ipo@kotak.com | www.investmentbank.kotak.com |
Understand company details, IPO size, price band, lot size, exchange listing, fresh issue and Offer for Sale (OFS) in simple language for retail investors.
This IPO is of CORONA Remedies Ltd. The issue is scheduled to open on Monday, 08 December 2025 and closes on Wednesday, 10 December 2025.
After the IPO process is completed, the shares are proposed to be listed on both NSE and BSE.
IPO size means the total amount offered to investors through the public issue.
For CORONA Remedies Ltd IPO, the total issue size is Rs 655.37 crore, consisting of an Offer for Sale (OFS) of Rs 655.37 crore.
Price band is the price range within which investors can bid for shares in a book-built IPO.
For this IPO, the lower price band is Rs 1,008 per share and the upper price band is Rs 1,062 per share.
Lot size is the minimum number of shares an investor must apply for in an IPO. IPO applications are usually made in fixed lot multiples.
For CORONA Remedies Ltd IPO, the minimum lot size is 14 shares. At the upper price band of Rs 1,062 per share, the minimum application amount is Rs 14,868. Applications must be made in multiples of 14 shares.
Offer for Sale (OFS) means existing shareholders sell their shares to the public through the IPO.
For CORONA Remedies Ltd IPO, the Offer for Sale (OFS) size is Rs 655.37 crore. In an OFS, the selling shareholders receive the money, and the company usually does not receive funds from that portion.
Understand the important IPO dates, allotment process, refund schedule and listing timeline in a retail-friendly format.
The IPO opening date is the first day on which investors can apply for the public issue.
For CORONA Remedies Ltd IPO, the IPO opens on Monday, 08 December 2025.
The IPO closing date is the last day on which investors can submit, modify, or cancel their IPO applications.
CORONA Remedies Ltd IPO closes on Wednesday, 10 December 2025.
The tentative allotment date is the expected date on which the registrar finalizes the share allotment for valid IPO applications.
For CORONA Remedies Ltd IPO, the tentative allotment date is Thursday, 11 December 2025.
The tentative listing date is the expected date on which IPO shares begin trading on the stock exchanges.
CORONA Remedies Ltd IPO is expected to list on Monday, 15 December 2025.
After allotment, funds are unblocked or refunds are initiated for non-allotted investors, while allotted shares are credited to investors' demat accounts before listing.
For CORONA Remedies Ltd IPO, refund initiation is expected on Friday, 12 December 2025, and credit of shares to demat accounts is expected on Friday, 12 December 2025.
Understand IPO category-wise reservation, QIB quota, retail quota, HNI allocation, shareholder reservation and the meaning of structure columns in a simple format.
IPO structure shows how shares are divided among different categories of investors, such as QIB, Retail, NII/HNI, Employees, and Shareholders.
For CORONA Remedies Ltd IPO, the available categories in the structure table include QIB, Retail, Non-Institutional Investors (NII/HNI), Employees. The NII/HNI category includes SHNI and BHNI sub-categories. Investors can use this table to understand category-wise allocation before applying.
QIB stands for Qualified Institutional Buyers. This category includes mutual funds, banks, insurance companies, and other large financial institutions.
In CORONA Remedies Ltd IPO, 50% shares are reserved under the QIB category, with 30,58,007 shares offered, and an allocation amount of ₹324.76 crore.
The Retail category is reserved for individual investors and HUFs applying for up to Rs 2 lakh within the retail investment limit allowed under IPO rules.
In CORONA Remedies Ltd IPO, 35% shares are reserved under the Retail category, with 21,40,606 shares offered, and an allocation amount of ₹227.33 crore.
NII/HNI stands for Non-Institutional Investors / High Net-Worth Individuals. This category generally includes investors applying for more than Rs 2 lakh, above the retail investment limit.
In CORONA Remedies Ltd IPO, 15% shares are reserved under the NII/HNI category, with 9,17,403 shares offered, and an allocation amount of ₹97.43 crore.
SHNI stands for Small HNI. It is a sub-category within the NII/HNI category and generally refers to applications for more than Rs 2 lakh but not exceeding Rs 10 lakh.
In CORONA Remedies Ltd IPO, 5% shares are reserved under the SHNI sub-category, with 3,05,801 shares offered, and an allocation amount of ₹32.48 crore.
BHNI stands for Big HNI. It is a sub-category within the NII/HNI category and generally refers to applications for more than Rs 10 lakh.
In CORONA Remedies Ltd IPO, 10% shares are reserved under the BHNI sub-category, with 6,11,602 shares offered, and an allocation amount of ₹64.95 crore.
Employee reservation is a special quota reserved for eligible company employees, if applicable.
In CORONA Remedies Ltd IPO, 58,035 shares are offered under the Employee Reservation category, and an allocation amount of ₹5.85 crore.
Understand retail lot size, HNI application limits, employee category, shareholder category and investment amount calculations using the IPO lot table.
Lot size is the minimum number of shares an investor must apply for in an IPO. IPO applications are usually made in fixed lot multiples.
For CORONA Remedies Ltd IPO, the minimum lot size is 14 shares. At the upper price band of Rs 1,062 per share, the minimum application amount is Rs 14,868. Applications must be made in multiples of 14 shares.
Retail minimum application shows the minimum application size for retail investors.
For CORONA Remedies Ltd IPO, the Retail minimum application is 14 shares (1 lot) for about Rs 14,868.
Retail maximum application shows the maximum application size generally available under the retail category.
For CORONA Remedies Ltd IPO, the Retail maximum application is 182 shares (13 lots) for about Rs 1,93,284.
SHNI minimum application shows the minimum application size for the Small HNI category.
For CORONA Remedies Ltd IPO, the SHNI minimum application is 196 shares (14 lots) for about Rs 2,08,152.
SHNI maximum application shows the maximum application size available under the Small HNI category, when provided.
For CORONA Remedies Ltd IPO, the SHNI maximum application is 938 shares (67 lots) for about Rs 9,96,156.
BHNI minimum application shows the minimum application size for the Big HNI category.
For CORONA Remedies Ltd IPO, the BHNI minimum application is 952 shares (68 lots) for about Rs 10,11,024.
Employee minimum application shows the minimum application size under the employee category, if this category is available in the IPO.
For CORONA Remedies Ltd IPO, the Employee minimum application is 14 shares (1 lot) for about Rs 14,112 with a discount of Rs 54 per share.
Employee maximum application shows the maximum application size under the employee category, if provided in the lot size table.
For CORONA Remedies Ltd IPO, the Employee maximum application is 490 shares (35 lots) for about Rs 4,93,920 with a discount of Rs 54 per share.
Understand important financial figures in simple language using the financial statement data available for the IPO.
Financial Highlights show important numbers from the company's financial statements. These may include income, expenses, profit, assets, liabilities, cash flow and other financial information, depending on the data available for the IPO.
The table displays available financial data based on the IPO information currently available. Fields may differ from company to company depending on disclosures and reporting format.
Investors should read the table to understand the company's financial performance and financial position over different periods.
The table may help users review income, expenses, profitability, balance sheet position, cash movement or other financial information, depending on the available data.
Financial statement line items may differ because companies operate in different industries and may follow different reporting formats.
Some companies may provide detailed financial breakup, while others may present broader financial categories.
Investors should review income, expenses, profitability, debt position, asset base, liabilities and cash flow position together.
A single financial figure should not be used alone to judge the company.
Profit is important, but it does not show the full financial picture.
Investors should also review revenue quality, expenses, debt, assets, liabilities, cash flow, valuation and business risks.
Cash flow helps investors understand how money moves in and out of the business.
A company may report profit but still face cash flow pressure, so cash flow should be reviewed along with profit, debt and balance sheet information.
No. Financial Highlights are useful, but investors should also review valuation, peer comparison, KPI data, business risks, IPO pricing, management discussion and official offer documents such as the RHP or DRHP.
Understand how the company may be compared with similar businesses using the peer comparison data available for the IPO.
Peer Comparison means comparing the IPO company with businesses operating in a similar sector or industry.
It helps investors understand the company in a broader industry context.
Peer Comparison helps investors understand how the company can be compared with similar businesses using available financial or valuation metrics.
It is useful for context, but it should not be treated as a final investment conclusion.
Peer comparison metrics may differ depending on the companies selected, accounting format, business model and available public information.
Investors should compare only relevant and similar metrics.
Investors should use the peer comparison table as a reference point.
Available metrics should be read together with business model, scale, profitability, margins, debt, growth, valuation and IPO pricing.
No. Peer Comparison does not directly decide whether an IPO is good or bad.
It only provides context for comparison. Final analysis should include financial statements, KPI data, valuation, risk factors and official offer documents.
No. Peer Comparison is only one part of IPO analysis.
Investors should also review financial statements, KPI data, business risks, valuation, IPO pricing and company fundamentals.
Understand important KPI metrics in simple language using the key performance indicator data available for the IPO.
Key Performance Indicators, or KPIs, are financial and valuation metrics used to understand profitability, efficiency, leverage, return-based ratios and earnings performance.
They help investors understand the company beyond basic financial figures.
KPIs help investors assess profitability, capital efficiency, leverage, valuation and earnings quality.
They should be reviewed together with financial statements, peer comparison and IPO pricing.
KPI data may differ depending on the company, industry, financial disclosures and available offer document information.
Not every IPO may provide every KPI, and some metrics may not be applicable to every business.
Investors should read KPI metrics together instead of relying on one ratio.
A single KPI may not give the full picture unless it is reviewed with financial statements, peer comparison, business model and valuation.
No. High or low KPI values need context.
The meaning of a ratio may differ depending on industry, business model, debt level, growth stage, profitability and IPO valuation.
No. KPI data is useful, but it should not be used alone.
Investors should also review financial statements, peer comparison, business risks, valuation, IPO pricing and official offer documents such as the RHP or DRHP.